Progress in the treatment of psoriasis is undeniable. However, not everything Griffiths and colleagues discuss has come to ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition ...

Researchers at the University of Copenhagen have developed an electrospun nanofibre patch for the easier and more effective ...

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

Discover how immune checkpoint inhibitors, a revolutionary cancer therapy, increase psoriasis risk. Essential insights for ...

PASI was associated with GlycA levels and cardiovascular disease in both studies. GlycA levels were independently associated ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Psoriasis severity and systemic inflammation linked to cardiovascular disease: insights for better patient care.

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Vista, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced a strategic partnership with the National Psoriasis ...